Health technology company improves earnings and cash flow in Q3/22

0

These changes earned Reliq Health Technologies Inc. an upgrade in overall rating from independent investment research and advisory firm Jefferson Research.

Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN) strengthened cash flow and earnings in Q3/22, leading Jefferson Research to upgrade the company’s rating from telemedicine to Hold from Sell, as noted in a June 10 research note.

Jefferson rates companies on five metrics — cash flow quality, earnings quality, operating efficiency, balance sheet and valuation — to derive an overall score.

During Q3/22, Reliq achieved better quarter-over-quarter (QOQ) ratings in two categories: earnings quality and cash flow quality.

In terms of earnings quality, the area in which it performed best, the company went from Strongest to Strongest.

“With a reported net income of -$800,000 last quarter that was equal to the adjusted figure, Reliq’s net income quality is extremely high,” noted Jefferson Research.

In terms of cash quality, Reliq also shined. After increasing its cash flow to -$1.5 million from -$2.8 million QOQ, the company earned a strong rating, improved from weak.

Reliq’s low-risk valuation rating is also positive for Reliq.

“A favorable valuation (a lower risk or low risk rating) implies lower potential downside risk, as evidenced by a company’s price multiple below the corresponding industry average,” Jefferson explained. Research.

Areas where Reliq could improve are operational efficiency and the bottom line, Jefferson Research noted.

In the operational efficiency category, Reliq showed no change, again scoring low. Indeed, the life sciences company’s gross margin and asset turnover deteriorated in Q3/22. Gross margin fell to 65.1% from 74%.

“The lower margin indicates that Reliq’s competitive position has deteriorated and the company may not be able to obtain higher prices for its goods or services,” according to Jefferson Research.

On a positive note regarding operational efficiency, however, during the quarter, Reliq strengthened its earnings before interest and tax margin (to -29.7% from -93%), net margin, return on investment , its sales and general administrative expenses, and equity turnover.

On the balance sheet, Reliq has deteriorated QOQ from a low to low rating due to the deterioration of the rapid and current ratios. The lower current ratio, having dropped to 4.6 times from 7.3 times, indicates that Reliq has decreased the amount of its current assets relative to current liabilities. The drop in the quick ratio from 6.7 to 4.4 times shows that the company has reduced its total liquid assets compared to current liabilities.

“The balance sheet shows Reliq’s ability to pay its bills and fund future growth,” Jefferson Research wrote.


You want to be the first to know about interesting information Health services investment ideas? Sign up to receive the FREE Streetwise’ reports newsletter.

Subscribe

Disclosures

1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own shares in the following companies mentioned in the article: None. She or members of her household are compensated by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are Streetwise Reports billboard sponsors: Reliq Health Technologies Inc. Click here for important information on sponsorship fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is provided for informational purposes only and does not constitute a recommendation to buy or sell any securities.

4) The article does not constitute investment advice. Each reader is encouraged to consult their financial professional, and any action taken by a reader as a result of the information presented here is their own responsibility. By opening this page, each reader accepts and consents to the full Streetwise Reports Terms of Service and Legal Notice. This article is not an investment solicitation. Streetwise Reports does not provide general or specific investment advice, and information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the activities, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or their family members, as well as those interviewed for articles and interviews on the site, may take a long or short position in the titles mentioned. Directors, officers, employees or members of their immediate family are prohibited from making purchases and/or sales of such securities on the open market or otherwise from the time of the decision to publish an article until three days working days after the publication of the article. . The foregoing prohibition does not apply to articles that, in substance, merely restate previously published company announcements.

As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their households) hold securities of Reliq Health Technologies Inc., a company mentioned in this article.

Disclosures for Jefferson ResearchReliq Health Technologies Inc., June 10, 2022

This report is for informational purposes only for clients of Jefferson Research & Management and should not be construed as a complete investment recommendation. This report was prepared exclusively by Jefferson Research & Management. The information in this report is from sources believed to be reliable, but no warranty is given as to its accuracy and no representation is made that it is complete or that errors, if discovered, will be corrected.

1) Jefferson Research & Management and its personnel are not engaged in investment banking activities for the companies covered.

2) No employee of Jefferson Research & Management serves on the board of directors of any Covered Company and no outsiders serve on the board of directors of Jefferson Research & Management.

3) Employees of Jefferson Research & Management who trade stocks in rated companies are subject to trading restrictions prior to release (once identified) and for a period of one day following rating changes, but do not hold individually or collectively more than 1% of the outstanding shares of a covered company. No part of this report may be reprinted or transmitted electronically without the prior written permission of Jefferson Research & Management.

Reproduction of any information, data or material, including rankings (“Content”) in any form is prohibited except with the prior written permission of the party concerned. This party, its affiliates and its suppliers (“Content Providers”) do not guarantee the accuracy, adequacy, completeness, timeliness or availability of any Content and are not responsible for any errors or omissions ( negligent or otherwise), howsoever caused, or for the results obtained from using such Content. In no event shall the Content Providers be liable for any damages, costs, expenses, legal fees or losses (including loss of revenue or profits and opportunity costs) related to any use of the Content. A reference to a particular investment or security, a rating or any comment regarding an investment forming part of the Content does not constitute a recommendation to buy, sell or hold such investment or security, does not address the suitability of an investment or security and should not be considered investment advice. Credit scores are statements of opinion and not statements of fact.

Share.

About Author

Comments are closed.